The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved marstacimab (Hympavzi) for preventing bleeding in haemophilia A or B patients aged 12 and above, marking a significant advancement in treatment options.
This first-of-its-kind therapy offers a convenient weekly subcutaneous injection, potentially transforming the lives of approximately 2,000 UK patients.
Revolutionizing Haemophilia Treatment
Marstacimab’s approval by the MHRA on April 17, 2025, introduces a groundbreaking approach to managing haemophilia A and B without inhibitors.
Unlike traditional intravenous factor replacements that require multiple weekly infusions, marstacimab offers once-weekly subcutaneous injections via pre-filled pens.
This innovation not only simplifies the treatment regimen but also addresses common challenges such as venous access issues.
Benefits for Patients
- Enables self-administration after training, fostering patient independence
- Reduces annualized bleeding rates by 35% compared to prophylaxis
- Offers a non-factor prophylaxis option with simplified dosing
- Potentially lowers hospital visits and associated healthcare costs
- Improves quality of life with fewer injections compared to traditional therapies
A New Era in Haemophilia Care
The introduction of marstacimab marks the UK’s first anti-TFPI therapy approval, following similar endorsements by the FDA and EMA in 2024.
This development comes over four decades after recombinant factor concentrates revolutionized haemophilia care.
The BASIS trial data demonstrated marstacimab’s efficacy in reducing bleeding rates comparable to existing treatments like emicizumab but through a novel mechanism.
Navigating Future Challenges
While marstacimab presents promising benefits, long-term safety data remains limited. The cost-effectiveness of this new therapy will be crucial for its adoption within the NHS framework.
With existing therapies costing upwards of £150k per year, evaluating marstacimab’s economic impact will be essential for widespread implementation.
Expert Insights on Safety and Efficacy
The MHRA emphasizes ongoing safety monitoring through its Yellow Card scheme to ensure patient well-being.
Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said:
“Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.
This new type of treatment demonstrates our commitment to enabling access to safe, innovative and effective medicines. We’re assured that the appropriate regulatory standards for the approval of this medicine have been met.
As with all products, we will keep its safety under close review.”
Meanwhile, US trials reported injection-site reactions in over 10% of patients.
Additional Reading
Food for Thought
The approval of marstacimab represents a pivotal moment in haemophilia treatment within the UK. By offering a more convenient administration method and reducing bleeding rates significantly, it holds promise for improving patient outcomes while potentially easing healthcare burdens.
As further data emerges on its long-term safety and cost-effectiveness, its role in reshaping haemophilia care will become clearer.
Discover more of Todays Top Breaking News Stories!
Sources: UK Government, Pfizer, Medicines and Healthcare products Regulatory Agency, and AJMC.
Prepared by Ivan Alexander Golden, Founder of THX News™, an independent news organization delivering timely insights from global official sources. Combines AI-analyzed research with human-edited accuracy and context.
